CCR6 antagonist 1|cas:588674-64-0|西域试剂

CCR6 antagonist 1,99.55%

产品编号：Bellancom-151435| CAS NO：588674-64-0| 分子式：C₁₇H₁₂F₃NO₂| 分子量：319.28

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-151435	￥720.00	杭州北京（现货）
Bellancom-151435	￥1120.00	杭州北京（现货）
Bellancom-151435	￥2320.00	杭州北京（现货）
Bellancom-151435	￥3360.00	杭州北京（现货）
Bellancom-151435	￥5200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CCR6 antagonist 1

产品介绍

CCR6 antagonist 1 是一种 CCR6 拮抗剂，可抑制 CCL20/CCR6 信号通路。 CCR6 antagonist 1 可用于自身免疫介导的炎症性疾病的研究，如炎症性肠病 (IBDs)。

生物活性

CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).

体外研究

CCR6 antagonist 1 (compound 1b, 50 μM, 3 h) blocks the CCL20-induced CD4⁺ T cell migration.
CCR6 antagonist 1 (30 nM-300 μM, 20 min) inhibits miniGi recruitment to CCR6 induced by CCL20, and β-arrestin-1 recruitment to CCR6 and CCR5 by CCL20 and CCL5 (5 nM), respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay

Cell Line:	CCL20 (500 ng/mL)-induced CCR6⁺CD4⁺ T cell
Concentration:	0.5, 5, 50 μM
Incubation Time:	3 h
Result:	Inhibited CCL20-induced cell migration at 50 μM.

体内研究
(In Vivo)

CCR6 antagonist 1 (compound 1b, 1 mg/kg, s.c., twice daily for 3 days) alleviates TNBS-induced inflammatory responses in mice.
CCR6 antagonist 1 (1 mg/kg, s.c., twice, before and after zymosan treatment) shows anti-inflammatory effects
in Zymosan-induced peritonitis mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Murine model of colitis (5 mg/mouse TNBS-induced)
Dosage:	1 mg/kg
Administration:	Subcutaneous injection (s.c.), twice daily for 3 days.
Result:	Improved mice general conditions, attenuated macroscopic injury and counteracted neutrophils infiltration, both in the colon and in lungs.

Animal Model:	Zymosan-induced peritonitis mice
Dosage:	1 mg/kg
Administration:	Subcutaneous injection (s.c.), twice, before and after zymosan treatment
Result:	Significantly reduced the total protein content and myeloperoxidase activity in the peritoneal lavage.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Murine model of colitis (5 mg/mouse TNBS-induced)
Dosage:	1 mg/kg
Administration:	Subcutaneous injection (s.c.), twice daily for 3 days.
Result:	Improved mice general conditions, attenuated macroscopic injury and counteracted neutrophils infiltration, both in the colon and in lungs.

Animal Model:	Zymosan-induced peritonitis mice
Dosage:	1 mg/kg
Administration:	Subcutaneous injection (s.c.), twice, before and after zymosan treatment
Result:	Significantly reduced the total protein content and myeloperoxidase activity in the peritoneal lavage.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Murine model of colitis (5 mg/mouse TNBS-induced)
Dosage:	1 mg/kg
Administration:	Subcutaneous injection (s.c.), twice daily for 3 days.
Result:	Improved mice general conditions, attenuated macroscopic injury and counteracted neutrophils infiltration, both in the colon and in lungs.

Animal Model:	Zymosan-induced peritonitis mice
Dosage:	1 mg/kg
Administration:	Subcutaneous injection (s.c.), twice, before and after zymosan treatment
Result:	Significantly reduced the total protein content and myeloperoxidase activity in the peritoneal lavage.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (313.20 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1320 mL	15.6602 mL	31.3205 mL
5 mM	0.6264 mL	3.1320 mL	6.2641 mL
10 mM	0.3132 mL	1.5660 mL	3.1320 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式